A broad scientific study published in the journal Nature revealed that a rare genetic mutation may grant certain individuals extraordinary protection against heart disease and type 2 diabetes by altering how the body handles energy and fat.
اضافة اعلان
The study, which encompassed over one million people across three continents, identified rare mutations in a gene known as FNIP1. These mutations appear to significantly reduce the risk of developing cardiometabolic diseases, which represent the leading cause of death globally.
Findings indicated that carriers of these mutations—a rare group estimated at roughly 1 in 7,000 people—face a nearly 60% lower probability of developing cardiometabolic conditions.
Furthermore, these individuals exhibit improved blood lipid profiles, reduced blood sugar levels, and a healthier distribution of body fat.
How the Mutation Works
The FNIP1 gene typically regulates intracellular energy consumption by acting as a "brake" on energy burning, thereby allowing the body to store calories. However, when partially inactivated by this mutation, the brake is released, causing the body to burn energy rather than store it.
Researcher Luca Lotta noted that these mutations enable the body to consume, store, and utilize energy far more efficiently, explaining the observed protective effect.
Laboratory experiments corroborated these findings: deactivating the gene in human liver cells activated fat-burning pathways. Additionally, animal studies demonstrated that manipulating this pathway protected mice from weight gain, improved insulin sensitivity, and reduced liver fat—even when placed on a high-fat diet.
The study also underscores the critical role of fat distribution. Visceral fat (around internal organs) carries higher health risks compared to subcutaneous fat (stored under the skin). Mutation carriers exhibited a significantly more balanced fat distribution profile.
Researchers also identified other linked genes, including PDE3B, whose mutations demonstrated a stronger effect in women regarding improved lipid markers—opening the door to a deeper understanding of sex-based biological differences.
A Potential Alternative to Obesity Medications
The findings suggest that the impact of these mutations partially mimics the mechanisms of modern GLP-1 receptor agonist drugs used to treat obesity and diabetes. However, the key distinction is that the FNIP1 gene acts directly on the body's fundamental energy management mechanism rather than relying solely on hormonal signaling.
Nevertheless, researchers caution against rushing to translate these findings into pharmaceutical therapies, as it remains unclear whether safely inhibiting this gene in humans will yield the same benefits without causing severe side effects.
Future Prospects
The study highlights the vital role of human genetics in discovering novel biological pathways for therapeutic targeting. At the same time, it emphasizes that a long road remains before developing viable drugs based on this discovery.
Ultimately, while this rare mutation may serve as a crucial key to understanding how to prevent modern metabolic diseases, it currently represents a promising scientific insight rather than an immediate medical cure.
Al Arabiya
